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Joubert syndrome–related disorders (JSRDs) are a group of clinically and genetically heterogeneous conditions that share
a midbrain-hindbrain malformation, the molar tooth sign (MTS) visible on brain imaging, with variable neurological,
ocular, and renal manifestations. Mutations in the CEP290 gene were recently identified in families with the MTS-related
neurological features, many of which showed oculo-renal involvement typical of Senior-Lo¨ken syndrome (JSRD-SLS
phenotype). Here, we performed comprehensive CEP290-mutation analysis on two nonoverlapping cohorts of JSRD-
affected patients with a proven MTS. We identified mutations in 19 of 44 patients with JSRD-SLS. The second cohort
consisted of 84 patients representing the spectrum of other JSRD subtypes, with mutations identified in only two patients.
The data suggest that CEP290 mutations are frequently encountered and are largely specific to the JSRD-SLS subtype.
One patient with mutation displayed complete situs inversus, confirming the clinical and genetic overlap between JSRDs
and other ciliopathies.
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Joubert syndrome (JS [MIM 213300]) is an autosomal re-
cessive disease presenting with hypotonia, ataxia, neo-
natal breathing abnormalities, oculomotor apraxia, and
psychomotor delay.1,2 The neuroradiological hallmark of
JS is a complex midbrain-hindbrain malformation known
as the “molar tooth sign” (MTS), which originates from
the association of cerebellar vermis hypoplasia or aplasia,
horizontally oriented and thickened superior cerebellar
peduncles, and a deepened interpeduncular fossa.3 These
clinical and neuroradiological features are shared by at
least eight distinct syndromes termed “JS-related disor-
ders” (JSRDs), which additionally present with pleiotropic
involvement, mainly of the eyes and kidneys.4
The four major subgroups of JSRDs include (1) the
classic form (MIM 213300), largely restricted to brain in-
volvement and also occasionally displaying retinopathy
and postaxial polydactyly but rarely renal involvement;
(2) the oculo-renal form (referred to in this article as
“JSRD-SLS”), which associates JS neurological features
with the Senior-Lo¨ken syndrome (SLS [MIM 266900])
phenotype of nephronophthisis (NPH [MIM 256100]) and
retinal dystrophy (either Leber congenital amaurosis [LCA
{MIM 204000}] or retinitis pigmentosa); (3) the subgroup
with preaxial or mesaxial polydactlyly and orofacial de-
fects, such as lobulated tongue, notched upper lip, or
cleft lip/palate, known as the “orofacial-digital type VI”
(OFDVI, or Varadi-Papp [MIM 277170]) syndrome; and (4)
the subgroup with choroidoretinal coloboma and hepatic
fibrosis, referred to as the “cerebellar vermis hypoplasia/
aplasia, oligophrenia, ataxia, ocular coloboma, and he-
patic fibrosis” (COACH [MIM 216360]) syndrome.
The genetic bases of JSRDs are only partially under-
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stood. Two loci, JBTS1/CORS1 and JBTS2/CORS2, have
been mapped to chromosomes 9q34.3 and 11p12-q13.3,
respectively, in a limited number of families,5–7 whereas
mutations in the AHI1 gene have been shown to account
for ∼10% of patients with JSRD, who mostly display the
classic form of the disease.8–11
Recently, we and others identified pathogenic muta-
tions in the CEP290 gene, which encodes a centrosomal
protein, in 13 families with JSRD.12,13 CEP290 protein was
localized to the base (centrosome) and stalk of primary
cilia, suggesting that JSRDs constitute one of the “cilia-
related” group of disorders. This point is strengthened by
the clinical overlap between JSRDs and other ciliopathies,
including infantile and juvenile NPH (either isolated or
associated with retinal dystrophy, which is known as “SLS”),
Meckel syndrome (MKS [MIM 249000]), and Bardet-Biedl
syndrome (BBS [MIM 209900]).14 Further reinforcing this
link, NPHP1 homozygous deletions that are a frequent
cause of isolated juvenile NPH and SLS and mutations in
MKS3 that are usually responsible for MKS have been de-
tected in rare cases of JSRDs.15–17
Among the 13 families with JSRD with CEP290 muta-
tions reported so far, the majority had JSRD-SLS, in line
with the pleiotropic features observed in most ciliopathies.
Few patients displayed incomplete phenotypes lacking ei-
ther renal or retinal involvement and additional signs,
such as occipital encephalocele.12,13 Intriguingly, mutations
in CEP290 have also been shown to be the most frequent
cause of isolated LCA, in the absence of any renal and
neurological involvement.18,19
The prevalence of CEP290 mutations among patients
with JSRD-SLS, as well as their role in causing other MTS-
associated phenotypes and genotype-phenotype corre-
lates, are still unknown. In this study, we sought to address
these issues by performing CEP290 mutation analysis in
the largest series to date of probands representative of the
whole JSRD clinical spectrum.
Subjects and Methods
Patient Ascertainment
Databases located at the IRCCS CSS, Mendel Institute (Rome)
(AISJAC database), at the University of California–San Diego (San
Diego) (Center for Cerebellar Malformations), and at the JS Foun-
dation were screened for patients with a definite diagnosis of JSRD
and neuroradiologically proven MTS. Patients were referred to
these two centers from 120 countries on all continents through
European and U.S. referral centers. Samples were obtained from
referring physicians or through the JS BioBank. Whenever avail-
able, detailed clinical data were collected by means of a stan-
dardized questionnaire to assess the possible involvement of all
organs, including diagnostic testing for ocular, renal, hepatic, and
skeletal features.
From these databases, we selected two groups of patients for
CEP290 screening. The first cohort consisted of 44 probands with
definite or probable JSRD-SLS. Thirty-two patients met the fol-
lowing inclusion criteria for definite JSRD-SLS: (1) presence of
MTS, (2) renal signs of NPH (end-stage renal disease [ESRD] and/
or typical ultrasound features and/or proof of impaired urinary-
concentration ability), and (3) either LCA or progressive retinitis
pigmentosa. In this group, we also included 12 children younger
than 10 years presenting a cerebello-ocular phenotype with MTS
and LCA but with no obvious renal involvement, who had not
yet undergone proper urinary-concentration testing or ultra-
sound examination. In our experience, the risk of a child with
LCA within this age group developing a renal disease is 150%;
thus, these 12 patients were given diagnoses of “probable JSRD-
SLS.”
The second cohort consisted of 84 probands representative of
the complete spectrum of the remaining subgroups of JSRDs,
including classic JS ( ), JS plus ocular involvement butnp 42
without renal involvement by age 10 years ( ), JS plus NPHnp 21
or cystic kidney disease without retinal involvement ( ),np 5
COACH syndrome ( ), and OFDVI syndrome ( ). Fivenp 6 np 5
patients had a proven MTS, but clinical details were not sufficient
to assign them to a specific phenotypic subgroup. Informed con-
sent was obtained from all families, and the study was approved
by the local ethics committees.
Mutational Analysis
The 128 probands with JSRD were analyzed for CEP290 mutations
after a three-step strategy.10 In brief, a denaturing high-perfor-
mance liquid chromatography (DHPLC)–based analysis was first
performed on DNA from one parent of each proband. All exons
identified as carrying abnormal elution profiles were sequenced
in both directions, and, subsequently, all parental mutations were
tested in the affected offspring and, in case of homozygosity, in
the other parent as well. Finally, heterozygous patients underwent
complete gene analysis by direct sequencing in both directions
to identify the second mutation. This strategy allowed DNA from
affected children (which is usually scarce and difficult to reobtain)
to be preserved and DHPLC limits in identifying homozygous
mutations to be overcome. PCRs were performed in a final volume
of 25 ml containing 40–80 ng genomic DNA, 1 U AmpliTaq Gold
(Applied Biosystems), 15 pmol of each primer, 1.5–2 mM MgCl2,
75 mM of each deoxyribonucleotide triphosphate, and 1# PCR
Buffer (Applied Biosystems), through the use of a GeneAmp PCR
system 9700 (Applied Biosystems). Samples were run on a Wave
DNA Fragment Analysis System (Transgenomics) at column tem-
peratures recommended by Navigator Software version 1.5.4
(Transgenomics). Bidirectional sequencing of purified PCR prod-
ucts (Millipore) was performed by using BigDye chemistry and
an ABI 3100 Capillary Array Sequencer (Applied Biosystems).
Primers and conditions for PCR and DHPLC are listed in table 1.
The common NPHP1 homozygous deletion, the intronic
CEP290 mutation recurring in isolated LCA (c.29911655ArG),
and mutations in the AHI1 gene were excluded in all probands,
in accordance with published protocols.10,16,18
Results
CEP290 Mutations
We identified 23 distinct CEP290 mutations in 21 families.
Seventeen mutations were novel, whereas six had been
reported elsewhere (tables 2 and 3).12,13,19 Six probands
were homozygous for CEP290 mutations, and 10 were
compound heterozygous, whereas, in 5 probands, only a
single mutated allele could be found. All mutations re-
ported were either nonsense or frameshift mutations re-
sulting in a predicted truncated protein. Most mutations
106
Table 1. Primers and PCR and DHPLC Conditions for CEP290 Analysis
Exon(s) Primer Sequence (5′r3′)
Amplicon
Size
(bp)
PCR Annealing
Temperature
(C)
No. of
Cycles
DHPLC Oven
Temperaturea
(C)
Buffer B Starting
%a
2 ACCAATAATACTGTGTACCTTG CAGATTGTGACAATTATAGTTG 289 58 38 53.1/57 54.4/52.1
3 CAACTATAATTGTCACAATCTG GTTCCACTAATAGCCAAACC 212 58 32 55.7 50.9
4 GTGCTTACATTCCAGTATAAAG GTTTAATGAACAAATGGAATTCA 186 58 32 54.4/58 53.4/49
5 ACCTTATAATCATGATGGACTC AATAACCATGATTACAATCATCC 285 58 32 51.8/53.4 54.3/54
6 TTGTTGACTCATTTGAACCTC AAAAAGCCAGGTAACTTGAAC 264 58 32 53.2/56.4 55.6/54.2
7 ACTGCTGAATTTTATCTTCTTC TTAGAAGACTCCAGTCCTGG 208 58 32 55.7 51.2
8–9 CAAGATAATATGCATCATTTTCCC ATGAAATTAAAGTTTTTAGGAACC 472 58 32 55 58.7
10 AGAGGACACTTATGGCTGCG GTAATGAGATAATATGAAGTCTG 332 56 35 52.9/54.1 56.3/54.6
11 CACATATGTAATGTAATGTATCC CTAATAAACGTGTTATAAACCAG 364 56 35 52.4/55.2 55.8/54.7
12 GTATCATAAATCTACTAACGGTG ATCGTTCAGAGTTCCAACTG 284 58 35 54/55.4 55.9/55.5
13 CTTGTACCCACAAGAAAATATG AGAAAACTCAATATTGACTTGAC 341 56 35 52.7/54.3 55.8/52.8
14 TGATTTGAAGGAATAAGTAGTC CTGTGAATGGCAAGAATAATTC 282 58 35 55/56.1/58 57.2/56.1/52
15 GTACATTTTCCTTTAGACTTAG ACTTGTAAATCAGGTTGCGC 311 58 38 54.1/56.6 55/52.5
16–17 CATTTTTGCAGCTTATTTGAATG ATATCCAGACAACTCACTTATC 380 58 38 54.8/55.8 57.9/56.9
18 ATTAAAGTGTTGGAATAGTAGG TATTTTCCTTTACTCTCTTTGC 218 58 38 55.3 50.1
19 ATTGATCAAACTTTTCTTAACTTG ACAGAGGTAATTAGGAGTAAAG 293 54 35 54 56.2
20 CCAATGATGTCTTTGGTATATG AAATATCTCATCAGAAACTATGG 340 58 38 54.5/55 57.8/57.3
21 GTCCATTTTATTTAAAGACAGAC TTAATTCAAGGGGCATTTTCTC 362 58 35 53.6/57.4 56.7/52.9
22 TATGGTTGAGGTAAAATTCCTG AGTACTATCTGCATGCTTTGG 390 58 38 52.6/55.8 58.9/54.2
23 TAACTTTCCTATAATGTTGTCAG TAAGTTCCTAACAGTAGTTACC 372 54 35 53.2 57.3
24 ATACCTCTTGTGTTGAGAAAAC CACAAAGACACATCCATATTAC 300 54 35 53.3/54.5 56.7/54.7
25 TATGCAATATTGTACAAAGTAGG TGATACCATCCTATCTTCTGC 368 58 38 54.5/55.4 58.7/57.8
26 AAAGTGGCTAGTGCTTGACC TGTTAAATTTATATAAATGCAGGC 358 54 35 56.3 57.9
27 AACTGGATTGTGAGTTTTAAGG AGGATTATTCATCTGCCTAAG 383 58 38 52.7/54.8 57.3/53.7
28 ACAGCATCTAAAATATCTGAGG AGATCCAGACAAACCACTTAAC 369 58 38 54.4/56.6 57/54.4
29 AAGGCCAAGTAAAGAGGATTG TACTACTAAGAATTGTATACCTG 349 58 35 55/56.9 58/55.8
30 TAGAAAGTGTACTTAATTGTTCC CCCACTCCCAACATCTAATG 231 58 38 56.2/58 55/52
31 AATCTGTGATAACTTTCACTGG TGTTTGCACCACTGAACTCC 604 58 35 54.7/58 61.2/56.5
32 CATTATCATCAATGGAGGAATG TAGTCATTTGTGCAATATTCTTG 603 58 35 53 61.7
33 CCTGTTATGTGCCTGATGTC TGAGTTAACACTCTAGACTATG 222 58 38 56.8/58.1 55.5/54
34 ATCTATGTTTTATCATACAGCTG ATCATTCTATGCATTGCCCTC 321 58 38 54.6/56.9 57.5/54.6
35 GCATTTTAAAGGGAAAAAGATAC CACTTTAGGGTAAAATAATATTTAG 402 54 37 53.5/55.4/57.5 58.1/56.1/54.1
36 ATATGGAGATACTGTTTCTTCC GCTGAATTTTAATTTACATGGTC 305 58 38 55.6 55.2
37 AATATGGAATAAGTATGGCATTG AGCAAACACTTATGTTTATCTTC 337 58 38 52.4/54.4/57.8 58.1/56.1/52.7
38 GTGACAGAGTGAGACTGGG ACAACACGGAGATTTATACTAC 397 58 38 54.8/56.4 57.7/56
39 ATAGTAGGAAGTAATAAAGCTTG TAGTGAATTCTCTTCCAATAGG 305 58 38 57.5/59.2 55/53
40 GTTCCTTTTATCATTGATACTTC AAGTAGAAATAAACTACTACCTC 352 58 38 52.6/53.8 58.6/57.4
41 GTGATAGCTTCAGAAAGTTGC CAGAATTAATACAGCCAGGTC 342 58 38 55.3 54.3
42 AACATATTTACATATTCTCTAGG TAAAGCTATATAATTTCCAGGTC 345 54 38 55.2 54.4
43 TTTGGTTTGGTAATGAGTATGC TTCAATTTCTAGGGGTCAACC 301 58 38 55/56.6 56.8/55.2
44 ACACTGAACTTTTCTTTTTTTATC AGATGTAATGCTTTTGGCCAG 320 58 38 54.4/57.6 56.7/52.7
45 TATCCAGTATGTCTTTTATGGC ACCATCACCATGATATATTAGG 329 58 38 53.9/55.7 56.4/53.2
46 TTTGCCTTTTCTTTTCAATGGC TATCTAAACTTTTCATTTCTGGC 223 58 38 56.2/57.7 53.4/51.9
47 TGTTGTATTGTTGGTACTTCG TTAGCCTTGCCTCTCATAAG 394 56 35 53/54.9 57.9/56
48 TGGTTTCTAAAACTACTTTGAAG ACTTCCAGTTTTTCCAAGAGG 296 58 38 53.3/54.4/57.2 55.5/54.4/51.6
49 TAGAGCCCCAGGTTATTTTTG TGTTCATCAGGAAGAAACCAG 293 58 38 54.2/56.1/58.5 59.5/56.5/53
50 TTAGTACAGTTATTTGAACTGAC ACAATGCAAGGAACATCTTGC 293 58 38 53.7/55.2 56.6/53.5
51 ACGCTTTGTTAAAAATGTGTATC ATGCTTGTCTCTAGTTGTAGC 255 58 38 55.5/58.9 52.7/46.2
52 TCACTAGTTCATAAGAAATGCC AATTCGATTTTACAGGGAGAC 291 58 38 55.1/56.6 56.2/54.2
53 CCATTACCTTGAACTCATTCG TAGGATACGTAGTTAAAGATGG 230 58 38 54.2/55.9 54.2/51.5
54 ATTCAGGAATACTTTGGCTTTC TTCGGAGAACTGCTTATTTCC 418 58 38 53.6/55.5 57.7/52.9
a Each value is a different optimized oven temperature, with the corresponding buffer B starting percent for each corresponding temperature at which the amplicon has been analyzed. For
some amplicons, to ensure adequate peak separation, we needed to run at a different temperature and buffer B starting percent. In those instances, duplicate values for both are represented.
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Table 3. Recurrent Mutations Identified in the CEP290 Gene
Phenotype and
DNA Mutation
Predicted
Protein
Alteration Exon
No. of
Families Referencesa
JSRD only:
5668GrT G1890X 41 10 Valente et al.,12 Sayer et al.,13 PD
4393CrT R1465X 34 3 PD
LCA only:
29911655ArG C998X 26 44 den Hollander et al.,18 Perrault et al.19
55871GrC Splice 40 4 den Hollander et al.18
5850delT F1950fsX1964 42 3 den Hollander et al.18
6604delA I2203fsX2226 48 2 den Hollander et al.18
JSRD and LCA:
4723ArT K1575X 36 8 Perrault et al.,19 PD
5163delIT T1721fsX1723 38 4 Perrault et al.,19 PD
3167_3175insA I1055fsX1069 28 3 Sayer et al.,13 Perrault et al.,19 PD
4882CrT Q1628X 37 3 Perrault et al.,19 PD
3814CrT R1272X 31 2 den Hollander et al.,18 PD
7341–7342insA L2448fsX2455 54 2 Sayer et al.,13 den Hollander et al.18
a PD p present data.
(20 of 23) clustered from exon 28 to the end of the gene,
with a peak at exon 41 (fig. 1). The most common mu-
tation was G1890X, which was homozygous in three fam-
ilies (two from the United Arab Emirates and one from
Turkey) and heterozygous in three others (from Italy, Ire-
land, and the United Kingdom). The R1465X mutation in
exon 34 recurred in three families (from Belgium, Brazil,
and the United States), and the Q1628X (exon 37) mu-
tation in two (from the United States and Russia), whereas
the remaining 20 mutations were all found in single fam-
ilies (table 2). All mutations segregated with the disease
in familial cases. CEP290 nucleotide variants representing
either polymorphisms or nucleotide changes of unknown
significance are listed in table 4.
Phenotypes Associated with CEP290 Mutations
JSRD-SLS subgroup.—CEP290 mutations were identified
in 16 (50%) of 32 probands with definite JSRD-SLS and in
3 (25%) of 12 patients with probable JSRD-SLS. All patients
had neurological signs typical of JS and a neuroradiolog-
ically proven MTS (fig. 2). Fifteen had sporadic cases of
disease, whereas four had one affected sib.
Among the 16 probands with definite JSRD-SLS, 15 pre-
sented with LCA and blindness within the 1st year of life,
whereas only 1 (MTI154) had progressive retinitis pig-
mentosa, with visual reduction documented at age 6 years.
One patient (MTI133b) had chorioretinal colobomas in
addition to LCA. All patients had signs of infantile or ju-
venile NPH; the youngest was age 2 years. Eight of them
had already developed ESRD at ages ranging between 4
and 18 years. Four patients with sporadic cases presented
additional clinical features, including a small occipital en-
cephalocele (COR083), atrial (COR003) or ventricular car-
diac septal defect (MTI154), and complete situs inversus
(MTI273) (fig. 3).
Three patients with mutations were given diagnoses of
probable JSRD-SLS, since they had LCA but no overt signs
of renal involvement by ages 2, 6, and 10 years. However,
evaluation of urinary-concentration ability after water
deprivation or desmopressin challenge had not been per-
formed, and the presence of an asymptomatic urinary-
concentration defect could not be excluded. One patient
presented additional clinical signs, including chorioretinal
colobomas, postaxial polydactyly, lobulated tongue, and
cardiomegaly (MTI487) (table 2).
Other JSRD subgroups.—The screening of the CEP290
gene among a second cohort with MTS yielded mutations
in only 2 (2%) among 84 probands, one with classic JS (1
of 42) and one with JS plus NPH (1 of 5). No mutations
were found among 21 patients with JS plus ocular in-
volvement, 6 with COACH syndrome, 5 with OFDVI syn-
drome, and 5 with proven MTS but limited clinical data
for subgroup assignment.
Between the two patients with mutations, the one clas-
sified as having pure JS presented no overt signs of retinal
or renal involvement at age 8 years, and results of kidney
ultrasound examination were normal. Yet, the possibility
that this child might develop a renal disease phenotype
with increasing age cannot be ruled out. The second pa-
tient with mutation had urinary-concentration defect but
normal vision and no signs of retinal involvement at age
5 years. Both patients were homozygous for the recurrent
G1980X mutation.
Discussion
In this study, we identified 17 novel CEP290 truncating
mutations, raising to 65 the number of known deleterious
alterations found in patients with JSRD and/or LCA.12,13,
18,19 Most mutations appear to be private, with only 12
mutations recurring in two or more families (table 3). Be-
sides the most common mutation—C998X, which is re-
stricted to LCA—our data show that G1890X represents
the second-most frequent CEP290 mutation. Interestingly,
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Figure 1. Schematic of distribution of mutations identified in this study across the 54 exons of CEP290. Numbers of patients with
mutations are listed in parentheses.
Table 4. Polymorphisms and Variants Observed in the CEP290 Gene
DNA Alteration
Reference
SNPa
Predicted
Protein
Alteration
Exon or
Intron
Allele
Frequencyb
(np 204
Chromosomes)
IVS536ArG ss69374911 … Intron 5 Common
c.829GrC ss69374912 E277Q Exon 10 Common
c.930ArG … V310V Exon 11 NS
c.1991ArG … D664G Exon 20 NS
IVS2030delT … … Intron 20 NS
c.2055TrC ss69374913 A685A Exon 21 Common
IVS2144TrC ss69374914 … Intron 21 Common
c.2268GrA rs2468255 S756S Exon 22 Common
c.2343TrC … N781N Exon 22 NS
c.2512ArG rs11104738 K838E Exon 24 Common
c.2717TrG rs7970228 L906W Exon 25 NS
IVS3540_46delT rs11356711 … Intron 35 Common
c.4806GrA … T1602T Exon 36 NS
IVS4125ArC rs17015438 … Intron 41 Common
IVS4145GrC ss69374915 … Intron 41 Common
IVS475_12insT rs11405846 … Intron 47 Common
c.6684TrG … N2228K Exon 49 NS
IVS5137CrG ss69374916 … Intron 51 Common
IVS5322TrC ss69374917 … Intron 53 Common
a “rs” Refers to reference SNP number; “ss” refers to submitter SNP number.
b Common p allele frequency 12%. NS p variation found in the parent but not
segregating in affected offspring.
this aberration seems to be strictly associated with the
JSRD phenotype, since it was never reported in large co-
horts of patients with isolated LCA. Yet, other recurrent
mutations have been described in families with both JSRD
and LCA, making it difficult to establish genotype-phe-
notype correlates. Of note, whereas mutations causative
of isolated LCA appear to be homogeneously distributed
throughout the gene,18,19 180% of mutations identified in
families with JSRD cluster in the second half of the gene.
We, as well as others,13,19 failed to identify the second mu-
tation in ∼20% of CEP290 families despite extensive se-
quencing of the whole coding region and canonical splice
sites. The possibility that other mutations reside within
intronic sequences (as is the case for the recurrent C998X
mutation)18 or represent large genomic rearrangements
needs to be further explored.
We found that CEP290 is a major causative gene of def-
inite JSRD-SLS, with demonstrable deleterious mutations
detected in half of the patients in this subgroup. The renal
disease phenotype was characterized mostly by juvenile
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Figure 2. Brain magnetic resonance imaging results for 12 of 21 probands with mutations, showing the typical midbrain-hindbrain
malformation known as the MTS. All panels display axial sections at the pontine or pontomesencephalic junction showing the MTS. A–
L, respectively, patients MTI012, MTI286, COR002a, COR083, COR145, COR109, COR084, COR125, MTI333b, MTI154, MTI125, and MTI487.
NPH, with development of renal failure toward the end
of the 1st decade or early in the 2nd decade. However, the
age at onset of renal failure was found to be extremely
variable, with the youngest patient aged 4 years. Thus,
patients with CEP290 mutations can also develop the in-
fantile form of NPH with rapid progression toward renal
failure within the first few years of life.
We also identified mutations in three children with ret-
inal blindness but no overt clinical signs of NPH by age
10 years (probable JSRD-SLS). It will be crucial to follow
up these patients to evaluate whether they will develop
renal disease later in life, to define the prognostic value
of CEP290 mutations in predicting NPH. This issue carries
important implications for genetics counseling of families
and for the setup of early interventional strategies aimed
at delaying the progression toward renal failure and min-
imizing complications such as growth retardation or bone
disease.
The ocular phenotype observed in patients with JSRD-
SLS is usually characterized by LCA. Yet, patients with rarer
cases show no detectable defects in vision within the 1st
year of life but later develop a progressive phenotype of
retinitis pigmentosa, usually with some residual sight. By
screening patients with other non–JSRD-SLS phenotypes,
we identified pathogenic mutations in two children with
preserved vision and normal ophthalmologic testing at
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Figure 3. Patient MTI273, homozygous for the S1595fsX1599 mutation in exon 36 of the CEP290 gene and presenting with JSRD-SLS
associated with complete situs inversus. Sagittal (A) and axial (B) brain magnetic resonance imaging sections show the MTS malformation.
C, Face showing absence of specific dysmorphic features. D, Kidney ultrasound displaying multiple renal cysts and increased echogenicity.
E, Chest x-ray showing complete situs inversus, with stomach bubble and heart apex on the patient’s right side (R).
ages 5 and 8 years (MTI012 and MTI587, respectively).
Intriguingly, we noticed that these two patients, as well
as the single child with JSRD-SLS with retinitis pigmentosa
who was not blind at age 6 years (MTI154), were the only
three to be homozygous for the recurrent G1890X mu-
tation in exon 41. This correlation holds true also for pa-
tients described elsewhere. In fact, of nine patients ho-
mozygous for this mutation, only one was reported to
have LCA,12,13 leading us to speculate that this truncating
mutation, through unknown mechanisms, might spare
the retina. Conversely, other truncating and splice-site
mutations, including the recurrent C998X, are invariably
associated with isolated LCA (table 3), and the rd16 mouse,
which carries an inframe 298-aa deletion of CEP290,
shows a pure retinal degeneration phenotype.18–20 There-
fore, there appear to be specific mutations that show pred-
ilection for one organ system over another. We excluded
the possibility of alternative splicing of implicated exons
as a mechanism of this selective organ sparing, because
they are present in all mRNAs represented in the UCSC
Genome Browser. This observation has not been reported
elsewhere for any known genetic disease, to our knowl-
edge, and warrants functional studies of these mutant pro-
teins in specific cell and animal models.
Among the 84 patients with other JSRD subtypes, we
identified no mutations other than the ones in the 2 pa-
tients without retinopathy. Therefore, it appears that the
clinical spectrum of CEP290 mutations is largely restrict-
ed to the JSRD-SLS phenotype. It is interesting to note
that one patient with mutation with probable JSRD-SLS
(MTI487) also presented additional clinical features rem-
iniscent of the OFDVI and COACH subgroups, such as
lobulated tongue, postaxial polydactyly of the hands and
feet, and bilateral chorioretinal colobomas. Although a
definite diagnosis of one of these syndromes could not be
made with the current classification system, the clinical
spectrum of MTS-associated features does require further
delineation.
In some patients with JSRD-SLS with CEP290 mutations,
we observed additional peculiar clinical features, expand-
ing the phenotypic spectrum to clearly overlap with other
ciliopathies. The first example is the presence in three pa-
tients (COR083 and two patients in the work of Sayer et
al.13) of occipital (meningo)encephalocele. This neural-
tube defect represents a constant feature of MKS, which
has been recently shown to be allelic to JSRD at the MKS3
gene.17 The second example is patient MTI273, a 10-year-
old Turkish boy presenting a JSRD-SLS phenotype asso-
ciated with complete situs inversus. Although this obser-
vation may be coincidental, this is unlikely because of the
rarity of both conditions and the report of similar phe-
notypes within the spectrum of ciliopathies. Mutations in
NPHP2, which encodes inversin, cause infantile NPH oc-
casionally associated with retinal dystrophy or with situs
inversus.21,22 Similarly, randomization of left-right body-
axis symmetry was reported in 4% of Finnish patients with
MKS23 and in a BBS-affected family with mutations in
BBS8.24 Of note, two other patients with CEP290 muta-
tions in our cohort (COR03 and MTI154) presented with
congenital heart malformations (atrial and ventricular
septal defect, respectively) that are often part of the clin-
ical spectrum of abnormalities observed in situs inversus.
The study of animal models with disrupted ciliary struc-
ture or function has highlighted a critical role for cilia in
regulating specific developmental pathways of neurula-
tion and left-right axis determination. In mouse embryos
lacking KIF3B, a protein essential for intraflagellar trans-
port (IFT) and ciliogenesis, the consequent lack of twirling
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nodal cilia led to a complex developmental phenotype of
growth retardation, randomized left-right axis asymmetry,
and neural-tube formation defects.25 Knockout mice for
distinct IFT proteins display neural-tube defects that are
consequent to disruption of the sonic hedgehog signaling
pathway,26–28 whereas a deletion of inversin in mouse or
knockdown in zebrafish resulted in renal cystic phenotype
with laterality defects.21,29
Since these proteins share several domains and have
been demonstrated to act in large protein-protein net-
works,14 it will be intriguing to investigate how CEP290
possibly interacts with other ciliary proteins to regulate
basic developmental mechanisms and sensory functions
in multiple tissues.
Acknowledgments
This work was supported by grants from the U.S. National Insti-
tute of Neurological Disease and Stroke, the Italian Ministry of
Health (Ricerca Corrente 2007; Ricerca Finalizzata 2005 Progetto
Malattie Rare grant number 526/A36), the Fondazione Pierfranco
e Luisa Mariani Organizzazione Non Lucrativa di Utilita Sociale,
the March of Dimes, the Burroughs Wellcome Fund Award in
Translational Research, and the National Institutes of Health.
Other members of the International JSRD Study Group are Pad-
raic Grattan-Smith (Sydney, Australia); Richard Leventer (Victo-
ria, Australia); Andreas Janecke (Innsbruck, Austria); Rudy Van
Coster (Ghent, Belgium); Karin Dias, Carla Moco, and Ana Mor-
eira (Porto Alegre, Brazil); Chong Ae Kim (Sa˜o Paulo); Gustavo
Maegawa (Toronto); Ghada M. H. Abdel-Salam, Alice Abdel-
Aleem, and Maha S. Zaki (Cairo, Egypt); Itxaso Marti and Susana
Quijano-Roy (Garches, France); Pascale de Lonlay and Alain Ver-
loes (Paris); Renaud Touraine (St. Etienne, France); Michel Koenig,
Clotilde Lagier-Tourenne, and Jean Messer (Strasbourg, France);
Heike Philippi (Mainz, Germany); Sofia Kitsiou Tzeli (Athens,
Greece); Saevar Halldorsson, Jonina Johannsdottir, and Peter Lud-
vigsson (Reykjavik); Alex Magee (Belfast); Dorit Lev and Marina
Michelson (Holon, Israel); Bruria Ben-Zeev (Ramat-Gan, Israel);
Rita Fischetto and Mattia Gentile (Bari, Italy); Silvia Battaglia and
Lucio Giordano (Brescia, Italy); Loredana Boccone (Cagliari, It-
aly); Martino Ruggieri (Catania, Italy); Stefania Bigoni and Ales-
sandra Ferlini (Ferrara, Italy); Maria Alice Donati and Elena Pro-
copio (Florence, Italy); Gianluca Caridi, Francesca Faravelli, and
Gianmarco Ghiggeri (Genoa, Italy); Silvana Briuglia and Gaetano
Tortorella (Messina, Italy); Stefano D’Arrigo, Chiara Pantaleoni,
Daria Riva, and Graziella Uziel (Milan, Italy); Anna Maria Laverda
and Alberto Permunian (Padova, Italy); Stefania Bova (Pavia, It-
aly); Roberta Battini (Pisa, Italy); Maria Roberta Cilio, Marilu` Di
Sabato, Francesco Emma, Vincenzo Leuzzi, and Pasquale Parisi
(Rome); Alessandro Simonati (Verona, Italy); Asma A. Al-Tawari,
Laila Bastaki, and Ahmad Aqeel (Kuwait City); Mirjam M. de Jong
(Groningen, The Netherlands); Roshan Koul and Anna Rajab
(Muscat, Oman); Matloob Azam (Islamabad, Pakistan); Clara Bar-
bot (Oporto, Portugal); Berta Rodriguez (La Coruna, Spain); Ig-
nacio Pascual-Castroviejo (Madrid); Sinan Comu (Istanbul); Mus-
tafa Akcakus (Kayseri, Turkey); David Nicholl (Birmingham,
United Kingdom); C. Geoffrey Woods (Cambridge, United King-
dom); Christopher Bennett and Jane Hurst (Leeds, United King-
dom); Christopher A. Walsh (Boston); Saunder Bernes (Mesa, AZ);
Henry Sanchez (Fremont, CA); Aldon E. Clark (Laguna Niguel,
CA); Clement Donahue (San Francisco); Jin Hahn and Terence D.
Sanger (Stanford, CA); Tomas E. Gallager (Manoa, HI); William
B. Dobyns (Chicago); Cynthia Daugherty (Bangor, ME); Kalpathy
S. Krishnamoorthy and Dean Sarco (Boston); Trudy McKanna
(Grand Rapids, MI); Joanne Milisa (Albuquerque, NM); Wendy K.
Chung, Darryl C. De Vivo, Hillary Raynes, and Romaine Schubert
(New York); Alison Seward (Columbus, OH); David G. Brooks
(Philadelphia); Amy Goldstein (Pittsburg, PA); James Caldwell and
Eco Finsecke (Tulsa, OK); Bernard L. Maria (Charleston, SC); Ken-
ton Holden (Mt. Pleasant, SC); Robert P. Cruse (Houston, TX);
and Kathryn J. Swoboda (Salt Lake City, UT).
Web Resources
Accession numbers and URLs for data presented herein are as
follows:
AISJAC, http://www.aisjac.com
Center for Cerebellar Malformations, http://www.ccm.ucsd.edu
JS BioBank, http://www.joubertsyndrome.org/BioBank.asp
JS Foundation, http://www.joubertsyndrome.org/RegCoordinators
.asp
Online Mendelian Inheritance in Man (OMIM), http://www.ncbi
.nlm.nih.gov/Omim/ (for JS, JSRD, SLS, NPH, LCA, OFDVI,
COACH, MKS, and BBS)
Standardized clinical questionnaire for JSRD evaluation, http://
www.ccm.ucsd.edu/PatientQuestionnaire2004.pdf
UCSC Genome Browser, http://www.genome.ucsc.edu/
References
1. Joubert M, Eisenring JJ, Robb JP, Andermann F (1969) Familial
agenesis of the cerebellar vermis: a syndrome of episodic hy-
perpnea, abnormal eye movements, ataxia, and retardation.
Neurology 19:813–825
2. Boltshauser E, Isler W (1977) Joubert syndrome: episodic hy-
perpnea, abnormal eye movements, retardation and ataxia,
associated with dysplasia of the cerebellar vermis. Neuropa-
diatrie 8:57–66
3. Maria BL, Hoang KB, Tusa RJ, Mancuso AA, Hamed LM, Quis-
ling RG, Hove MT, Fennell EB, Booth-Jones M, Ringdahl DM,
et al (1997) “Joubert syndrome” revisited: key ocular motor
signs with magnetic resonance imaging correlation. J Child
Neurol 12:423–430
4. Gleeson JG, Keeler LC, Parisi MA, Marsh SE, Chance PF, Glass
IA, Graham JM Jr, Maria BL, Barkovich AJ, Dobyns WB (2004)
Molar tooth sign of the midbrain-hindbrain junction: oc-
currence in multiple distinct syndromes. Am J Med Genet A
125:125–134
5. Saar K, Al-Gazali L, Sztriha L, Rueschendorf F, Nur-E-Kamal
M, Reis A, Bayoumi R (1999) Homozygosity mapping in fam-
ilies with Joubert syndrome identifies a locus on chromosome
9q34.3 and evidence for genetic heterogeneity. Am J Hum
Genet 65:1666–1671
6. Keeler LC, Marsh SE, Leeflang EP, Woods CG, Sztriha L, Al-
Gazali L, Gururaj A, Gleeson JG (2003) Linkage analysis in
families with Joubert syndrome plus oculo-renal involvement
identifies the CORS2 locus on chromosome 11p12-q13.3. Am
J Hum Genet 73:656–662
7. Valente EM, Salpietro DC, Brancati F, Bertini E, Galluccio T,
Tortorella G, Briuglia S, Dallapiccola B (2003) Description,
nomenclature, and mapping of a novel cerebello-renal syn-
www.ajhg.org The American Journal of Human Genetics Volume 81 July 2007 113
drome with the molar tooth malformation. Am J Hum Genet
73:663–670
8. Dixon-Salazar T, Silhavy JL, Marsh SE, Louie CM, Scott LC,
Gururaj A, Al-Gazali L, Al-Tawari AA, Kayserili H, Sztriha L,
et al (2004) Mutations in the AHI1 gene, encoding Jouberin,
cause Joubert syndrome with cortical polymicrogyria. Am J
Hum Genet 75:979–987
9. Ferland RJ, Eyaid W, Collura RV, Tully LD, Hill RS, Al-Nouri
D, Al-Rumayyan A, Topcu M, Gascon G, Bodell A, et al (2004)
Abnormal cerebellar development and axonal decussation
due to mutations in AHI1 in Joubert syndrome. Nat Genet
36:1008–1013
10. Valente EM, Brancati F, Silhavy JL, Castori M, Marsh SE, Bar-
rano G, Bertini E, Boltshauser E, Zaki MS, Abdel-Aleem A, et
al (2006) AHI1 gene mutations cause specific forms of Joubert
syndrome-related disorders. Ann Neurol 59:527–534
11. Parisi MA, Doherty D, Eckert ML, Shaw DW, Ozyurek H, Ay-
sun S, Giray O, Al Swaid A, Al Shahwan S, Dohayan N, et al
(2006) AHI1 mutations cause both retinal dystrophy and re-
nal cystic disease in Joubert syndrome. J Med Genet 43:334–
339
12. Valente EM, Silhavy JL, Brancati F, Barrano G, Krishnaswami
SR, Castori M, Lancaster MA, Boltshauser E, Boccone L, Al-
Gazali L, et al (2006) Mutations in CEP290, which encodes
a centrosomal protein, cause pleiotropic forms of Joubert syn-
drome. Nat Genet 38:623–625
13. Sayer JA, Otto EA, O’Toole JF, Nurnberg G, Kennedy MA,
Becker C, Hennies HC, Helou J, Attanasio M, Fausett BV, et
al (2006) The centrosomal protein nephrocystin-6 is mutated
in Joubert syndrome and activates transcription factor ATF4.
Nat Genet 38:674–681
14. Hildebrandt F, Otto E (2005) Cilia and centrosomes: a uni-
fying pathogenic concept for cystic kidney disease? Nat Rev
Genet 6:928–940
15. Parisi MA, Bennett CL, Eckert ML, Dobyns WB, Gleeson JG,
Shaw DW, McDonald R, Eddy A, Chance PF, Glass IA (2004)
The NPHP1 gene deletion associated with juvenile nephron-
ophthisis is present in a subset of individuals with Joubert
syndrome. Am J Hum Genet 75:82–91
16. Castori M, Valente EM, Donati MA, Salvi S, Fazzi E, Procopio
E, Galluccio T, Emma F, Dallapiccola B, Bertini E (2005)
NPHP1 gene deletion is a rare cause of Joubert syndrome
related disorders. J Med Genet 42:e9
17. Baala L, Romano S, Khaddour R, Saunier S, Smith UM, Au-
dollent S, Ozilou C, Faivre L, Laurent N, Foliguet B, et al
(2007) The Meckel-Gruber syndrome gene, MKS3, is mutated
in Joubert syndrome. Am J Hum Genet 80:186–194
18. den Hollander AI, Koenekoop RK, Yzer S, Lopez I, Arends ML,
Voesenek KE, Zonneveld MN, Strom TM, Meitinger T, Brun-
ner HG, et al (2006) Mutations in the CEP290 (NPHP6) gene
are a frequent cause of Leber congenital amaurosis. Am J Hum
Genet 79:556–561
19. Perrault I, Delphin N, Hanein S, Gerber S, Dufier JL, Roche
O, Defoort-Dhellemmes S, Dollfus H, Fazzi E, Munnich A, et
al (2007) Spectrum of NPHP6/CEP290 mutations in Leber
congenital amaurosis and delineation of the associated phe-
notype. Hum Mutat 28:416
20. Chang B, Khanna H, Hawes N, Jimeno D, He S, Lillo C, Par-
apuram SK, Cheng H, Scott A, Hurd RE, et al (2006) In-frame
deletion in a novel centrosomal/ciliary protein CEP290/
NPHP6 perturbs its interaction with RPGR and results in
early-onset retinal degeneration in the rd16 mouse. Hum Mol
Genet 15:1847–1857
21. Otto EA, Schermer B, Obara T, O’Toole JF, Hiller KS, Mueller
AM, Ruf RG, Hoefele J, Beekmann F, Landau D, et al (2003)
Mutations in INVS encoding inversin cause nephronoph-
thisis type 2, linking renal cystic disease to the function of
primary cilia and left-right axis determination. Nat Genet 34:
413–420
22. O’Toole JF, Otto EA, Frishberg Y, Hildebrandt F (2006) Reti-
nitis pigmentosa and renal failure in a patient with mutations
in INVS. Nephrol Dial Transplant 21:1989–1991
23. Salonen R (1984) The Meckel syndrome: clinicopathological
findings in 67 patients. Am J Med Genet 18:671–689
24. Ansley SJ, Badano JL, Blacque OE, Hill J, Hoskins BE, Leitch
CC, Kim JC, Ross AJ, Eichers ER, Teslovich TM, et al (2003)
Basal body dysfunction is a likely cause of pleiotropic Bardet-
Biedl syndrome. Nature 425:628–633
25. Nonaka S, Tanaka Y, Okada Y, Takeda S, Harada A, Kanai Y,
Kido M, Hirokawa N (1998) Randomization of left-right asym-
metry due to loss of nodal cilia generating leftward flow of
extraembryonic fluid in mice lacking KIF3B motor protein.
Cell 95:829–837
26. Huangfu D, Liu A, Rakeman AS, Murcia NS, Niswander L,
Anderson KV (2003) Hedgehog signalling in the mouse re-
quires intraflagellar transport proteins. Nature 426:83–87
27. Marszalek JR, Ruiz-Lozano P, Roberts E, Chien KR, Goldstein
LS (1999) Situs inversus and embryonic ciliary morphogen-
esis defects in mouse mutants lacking the KIF3A subunit of
kinesin-II. Proc Natl Acad Sci USA 96:5043–5048
28. Takeda S, Yonekawa Y, Tanaka Y, Okada Y, Nonaka S, Hiro-
kawa N (1999) Left-right asymmetry and kinesin superfamily
protein KIF3A: new insights in determination of laterality and
mesoderm induction by kif3A/ mice analysis. J Cell Biol
145:825–836
29. Morgan D, Turnpenny L, Goodship J, Dai W, Majumder K,
Matthews L, Gardner A, Schuster G, Vien L, Harrison W, et
al (1998) Inversin, a novel gene in the vertebrate left-right
axis pathway, is partially deleted in the inv mouse. Nat Genet
20:149–156
